Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
OptimizeRx ( (OPRX) ) just unveiled an announcement.
On May 7, 2026, OptimizeRx entered a new $35 million senior secured credit facility with Fifth Third Bank, comprising a $25 million term loan and a $10 million revolving line, to refinance its October 2023 Blue Torch term loan, fund potential stock repurchases, and support working capital and general corporate needs. The seven-year facility, which includes an accordion of up to $25 million, carries leverage-based pricing, customary covenants and guarantees, and is expected to lower annual interest expense by about $1.5 million while providing added balance sheet flexibility.
For the first quarter ended March 31, 2026, OptimizeRx reported a 10% year-over-year revenue decline to $19.8 million, but narrowed its GAAP net loss to $0.5 million and more than doubled adjusted EBITDA to $3.3 million, supported by higher non-GAAP profitability and debt paydown of $2.7 million of principal. Management cited near-term headwinds from most-favored-nation pricing and cautious client spending, but reaffirmed confidence in long-term digital engagement trends, updated 2026 revenue guidance to $95 million to $100 million with unchanged adjusted EBITDA targets of $21 million to $25 million, and launched efficiency initiatives expected to yield $3 million in annualized savings, including $1 million this year.
Operationally, OptimizeRx is seeing solid traction with clients less exposed to MFN pressures and among mid-tier and emerging life sciences companies, while revenue concentration with top 20 pharma has moderated to 52% and net revenue retention stood at 110% over the twelve months ended March 31. By integrating programmatic DSP access into its EHR network and focusing on efficiency and lower-cost funding, the company is seeking to sharpen its competitive position in healthcare marketing technology and support a more profitable growth trajectory for stakeholders.
The most recent analyst rating on (OPRX) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on OptimizeRx stock, see the OPRX Stock Forecast page.
Spark’s Take on OPRX Stock
According to Spark, TipRanks’ AI Analyst, OPRX is a Neutral.
The score is driven primarily by stronger financial health and cash generation alongside improved profitability and low leverage. These positives are tempered by weak technical trends and a high P/E, plus conservative 2026 revenue outlook and near-term demand/contracting headwinds discussed on the earnings call.
To see Spark’s full report on OPRX stock, click here.
More about OptimizeRx
OptimizeRx Corp., based in Waltham, Mass., is a healthcare technology company that helps pharmaceutical and broader life sciences brands connect with healthcare professionals and patients. Its AI-driven platform, including the Dynamic Audience Activation Platform and Micro-Neighborhood Targeting, delivers privacy-safe, hyper-local digital engagement that synchronizes HCP and direct-to-consumer strategies to accelerate treatment decisions and improve patient outcomes.
The company partners with many of the world’s largest pharmaceutical manufacturers and emerging life sciences clients, leveraging a proprietary electronic health record network and deep point-of-care integrations. By opening its EHR network to demand-side platforms, OptimizeRx is positioning itself as a key conduit for programmatic, point-of-care media buying within clinical workflows, aiming to expand inventory utilization and unlock new high-growth revenue channels over time.
Average Trading Volume: 483,886
Technical Sentiment Signal: Sell
Current Market Cap: $120.8M
For an in-depth examination of OPRX stock, go to TipRanks’ Overview page.